Adicet Bio Issues Pre-Funded Warrant in Equity Exchange

Adicet Bio ( (ACET) ) just unveiled an update.

On April 27, 2026, Adicet Bio, Inc. entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. under which RA Capital exchanged 250,000 shares of Adicet’s common stock for a pre-funded warrant to acquire an equal number of common shares at a nominal exercise price of $0.0001 per share. The pre-funded warrant, issued in a private, unregistered transaction relying on a securities law exemption, is exercisable on a cashless basis and includes ownership and voting caps of 9.99%, adjustable up to but not exceeding 19.99%, effectively providing RA Capital with flexible future participation in the company’s equity while limiting immediate concentration of control.

The most recent analyst rating on (ACET) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Spark’s Take on ACET Stock

According to Spark, TipRanks’ AI Analyst, ACET is a Neutral.

The score is held down primarily by weak financial performance—no recent revenue, large ongoing losses, and significant cash burn despite low leverage. Technicals provide some offset with improving near-term trend signals, while valuation remains unattractive/unclear due to negative earnings and no dividend.

To see Spark’s full report on ACET stock, click here.

More about Adicet Bio

Adicet Bio, Inc. is a biotechnology company focused on developing innovative cell-based therapies. Operating in the biopharmaceutical sector, it concentrates on advanced treatments that leverage genetic and immunological technologies to address serious diseases, targeting investors and partners interested in cutting-edge therapeutic platforms.

Average Trading Volume: 149,363

Technical Sentiment Signal: Sell

Current Market Cap: $75.81M

See more data about ACET stock on TipRanks’ Stock Analysis page.